Previous Story
Aquinox Phama Stock Soars 4000% on Bladder Pain Results
Posted On Aug 10 2015
Comment: Off
The company’s report included positive results for Q2 2015.
“Consistently positive results from multiple secondary endpoints have strengthened our confidence in the further development of AQX-1125 for BPS/IC.The encouraging effect of AQX-1125 observed on the primary endpoint of reduction in pain together with several statistically significant secondary endpoints, underscore the potential of AQX-1125 as a once-daily, oral therapy for this debilitating disease”, said David Main, President and CEO of Aquinox Pharmaceuticals.
Aquinox Pharmaceuticals (AQXP) shares are continuing to rise following its 2015 second-quarter earnings report.
Aquinox Pharmaceuticals Inc.is up 47.59% in the last 3-month period.
Shares of Amarin Corporation plc (ADR) (NASDAQ:AMRN) were gained 14.22% versus prior close, having surged 139.98% this year. More than 11 million shares had changed hands Monday as of 11:30 a.m. ET – more than 50 times the stock’s 30-day average volume before the rally began Friday morning. By afternoon trading on the stock market today, it was up 221% at 33.41. Bio Therapeutic Drugs Amarin Corporation plc (ADR) (NASDAQ:AMRN) proclaimed a United States District Court has ruled that Amarin may promote to healthcare professionals certain uses of Amarin’s lead product, Vascepa®(icosapent ethyl) capsules, that are not covered by current FDA-approved labeling for the drug so long as the promotion is truthful and non-misleading. The company shares have rallied 37.83% in the past 52 Weeks.
In an interview with Benzinga, Biren Amin, an analyst at Jefferies commented (apparently not in a joking manner) that the shares of Aquinox Pharmaceuticals are fairly valued following the results of its Phase 2 trial for AQX-1125. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.12.
Is this a Buying Opportunity? Cowen and Company now has an outperform rating on the stock. 1 analysts have rated the company as a strong buy.
